Proteolysis-targeting chimeras
Proteolysis-targeting chimeras (PROTACs) are chimeric small-molecule therapeutics designed to eliminate selected intracellular proteins rather than merely inhibit their activity.
Proteolysis-targeting chimeras (PROTACs) are chimeric small-molecule therapeutics designed to eliminate selected intracellular proteins rather than merely inhibit their activity. A typical PROTAC contains two binding elements connected by a chemical linker: one recognizes a target protein and the other recruits an E3 ubiquitin ligase, such as cereblon (CRBN) or a von Hippel–Lindau (VHL) complex. Formation of the resulting ternary complex brings the target protein into proximity with the E3 ligase, promoting ubiquitination and subsequent destruction by the ubiquitin–proteasome system 42089481May.
Because PROTACs act through event-driven protein degradation, a single molecule can promote the removal of multiple target-protein molecules and may address proteins that are difficult to inhibit pharmacologically. This modality has consequently been investigated in cancer and other disease-oriented drug-discovery programs, including efforts to overcome drug resistance and degrade mutant EGFR. PROTAC research also addresses pharmaceutical limitations such as cellular uptake, potency, selectivity, oral bioavailability and tissue delivery. In the current literature, recurring strategies include CRBN- and VHL-recruiting degraders, prodrug design, self-assembly, liposomal delivery and combinations with other targeted-therapy approaches.
Where the papers sit
10 papers from the last 6 months study proteolysis-targeting chimeras directly · updated from PubMed 11 Nov 2026
Study type 0 clinical trials · 1 human data · 2 preclinical · 7 unclassified
Themes one subject · 1 new direction
Those 10 are all about one subject.
-
PROTAC Design and Delivery
Rational PROTAC design is moving beyond target degradation toward predictable drug-like behavior and exposure. Linker-based descriptors and chemical-probe fitness criteria aim to reduce trial-and-error during early discovery. Lipid nanocarriers, carrier-free self-assembly, and cereblon-recruiting prodrugs address bioavailability, pharmacokinetics, and tumor delivery. BTK and EGFR examples show efforts to translate these design principles into orally available or selectively delivered degraders.
PROTAC drug-likeness defects can serve as the basis of a carrier-free, theranostic nanoplatform
The cyanine-PROTAC assemblies for tumor-specific protein degradation treated PROTACs’ poor solubility, bioavailability, and distribution not merely as liabilities requiring conventional formulation or external carriers, but as forces that drive co-assembly with cyanine dyes into a carrier-free nanoplatform. The resulting assemblies combine high PROTAC loading with fluorescence tracking, stimulus-responsive release, and, with diselenide-bridged cyanines, radiosensitization, thereby extending PROTACs from degraders delivered by a formulation into components of an imaging- and radiotherapy-integrated therapeutic platform 42526644Jul.
Papers
The 10 papers from the last 6 months that study proteolysis-targeting chimeras directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
PROTAC Design and Delivery (10)
- The Exploration for the Bioavailability of PROTAC. Handbook of experimental pharmacology · 9 Nov 2026 PMID 43002244
- Limiting Trial-and-Error: Linker-Based 2D Descriptor Analysis to Support Very Early Proteolysis-Targeting Chimeras Design. ChemMedChem · 12 Oct 2026 PMID 42860805
- Engineering lipid-based nanocarriers for PROTAC delivery: evaluating the influence of manufacturing and morphology on pharmacokinetic exposure. International journal of pharmaceutics · 3 Oct 2026 PMID 42829009
- Fitness criteria for PROTACs as chemical probes: principles and applications. Essays in biochemistry · 24 Sept 2026 PMID 42779486
- The Delivery Strategies for PROTAC. Handbook of experimental pharmacology · 23 Sept 2026 PMID 42778650
- Proteolysis Targeting Chimeras (PROTACs): Design and Mechanism. Handbook of experimental pharmacology · 12 Sept 2026 PMID 42730807
- Discovery of Highly Potent and Selective, Orally Bioavailable BTK-Targeting PROTACs Featuring Novel CRBN-Binding Warheads. Journal of medicinal chemistry · 10 Sept 2026 PMID 42720469
- EGFR-Degrading PROTACs and Calcium Peroxide Co-loaded Liposomes: Enabling EGFR Degradation and Hypoxia Alleviation as Dual Safeguards for NSCLC Therapy. ACS applied materials & interfaces · 1 Sept 2026 PMID 42679142
- Generalizable Strategies for the Synthesis of Cereblon-Recruiting PROTAC Prodrugs. Angewandte Chemie (International ed. in English) · 5 Aug 2026 PMID 42554619
- Drug-likeness defects drive carrier-free cyanine-PROTAC self-assembly for tumor-specific protein degradation. Journal of controlled release : official journal of the Controlled Release Society · 29 Jul 2026 PMID 42526644
By study type
Human data, design not indexed (1)
- Limiting Trial-and-Error: Linker-Based 2D Descriptor Analysis to Support Very Early Proteolysis-Targeting Chimeras Design. ChemMedChem · 12 Oct 2026 PMID 42860805
Preclinical: animal, cell and lab studies (2)
- Discovery of Highly Potent and Selective, Orally Bioavailable BTK-Targeting PROTACs Featuring Novel CRBN-Binding Warheads. Journal of medicinal chemistry · 10 Sept 2026 PMID 42720469
- EGFR-Degrading PROTACs and Calcium Peroxide Co-loaded Liposomes: Enabling EGFR Degradation and Hypoxia Alleviation as Dual Safeguards for NSCLC Therapy. ACS applied materials & interfaces · 1 Sept 2026 PMID 42679142
Unclassified: not yet indexed with MeSH (7)
- The Exploration for the Bioavailability of PROTAC. Handbook of experimental pharmacology · 9 Nov 2026 PMID 43002244
- Engineering lipid-based nanocarriers for PROTAC delivery: evaluating the influence of manufacturing and morphology on pharmacokinetic exposure. International journal of pharmaceutics · 3 Oct 2026 PMID 42829009
- Fitness criteria for PROTACs as chemical probes: principles and applications. Essays in biochemistry · 24 Sept 2026 PMID 42779486
- The Delivery Strategies for PROTAC. Handbook of experimental pharmacology · 23 Sept 2026 PMID 42778650
- Proteolysis Targeting Chimeras (PROTACs): Design and Mechanism. Handbook of experimental pharmacology · 12 Sept 2026 PMID 42730807
- Generalizable Strategies for the Synthesis of Cereblon-Recruiting PROTAC Prodrugs. Angewandte Chemie (International ed. in English) · 5 Aug 2026 PMID 42554619
- Drug-likeness defects drive carrier-free cyanine-PROTAC self-assembly for tumor-specific protein degradation. Journal of controlled release : official journal of the Controlled Release Society · 29 Jul 2026 PMID 42526644
Written from 10 PubMed abstracts, each one listed by PMID above. Published: 2026-09-25. Last written: 2026-09-26 by GPT. Drafted by language models from published abstracts; not medical advice.